Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial

BACKGROUND: Most children with medulloblastoma fall within the standard-risk clinical disease group defined by absence of high-risk features (metastatic disease, large-cell/anaplastic histology, and MYC amplification), which includes 50–60% of patients and has a 5-year event-free survival of 75–85%....

Descripción completa

Detalles Bibliográficos
Autores principales: Goschzik, Tobias, Schwalbe, Edward C, Hicks, Debbie, Smith, Amanda, zur Muehlen, Anja, Figarella-Branger, Dominique, Doz, François, Rutkowski, Stefan, Lannering, Birgitta, Pietsch, Torsten, Clifford, Steven C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262170/
https://www.ncbi.nlm.nih.gov/pubmed/30392813
http://dx.doi.org/10.1016/S1470-2045(18)30532-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262170/
https://www.ncbi.nlm.nih.gov/pubmed/30392813
http://dx.doi.org/10.1016/S1470-2045(18)30532-1

Ejemplares similares